Potential new option for Alzheimer's patients
October 8, 2012 (WLS) -- Two large studies show patients with mild Alzheimer's disease taking an experimental drug had 34 percent less decline in memory over 18 months compared with those taking placebos.
The drug is called solanezumab. The analysis of data from two large studies were presented Monday at a medical meeting in Boston. But this closely watched drug did not significantly protect against loss of physical functions.
Scientists say the latest data lend further credence to the theory that Alzheimer's must be attacked early in the disease for drugs to have a clinically meaningful impact.
The drug works by blocking a protein called beta amyloid that forms plaque deposits on the brain.
- Boston bombing remembered 1 year later 12 min ago
- Firefighters, cop among 8 injured in South Side fire
- Priest Michael O'Connell reinstated by archdiocese
- ABC7 First Alert Weather Forecast
- Mother questions why Harvey police shot son
- Man shot in Palos Heights home invasion 31 min ago
- Local runners preparing for Boston Marathon
- Suspect sought in Boystown alley sex assault
- Loop bank robbery suspect arrested
- Drunk driver charged with driving 118 mph on I-55
- Police fatally shoot 'vicious' dog on South Side
- Teen smoking sees dramatic drop in Chicago
- Shedd announces female penguin chick's name
- abcnews: Experts: Pistorius May Have Stumbled on Stand